Changes to an Approved NDA or ANDA: Supplements and Reports

Any change to a drug product after FDA has approved the New Drug Application or Abbreviated New Drug Application must be classified by risk and routed through one of three regulatory pathways before the modified product can be distributed. The governing rule, 21 CFR 314.70, sorts changes to an approved NDA or ANDA into major, moderate, and minor tiers, each with its own submission type and implementation timeline.¹ ANDA holders follow the identical requirements under 21 CFR 314.97.² The pathway determines whether you must wait for FDA approval, wait 30 days, implement immediately, or simply report the change in your next annual report.

Classifying the Change

Classification turns on one question: how much could this change hurt the drug’s identity, strength, quality, purity, or potency, and therefore its safety or effectiveness? The answer places the change in one of three tiers.

Major changes have substantial potential for an adverse effect. They require a Prior Approval Supplement (PAS), and FDA must approve the supplement before the modified product can be distributed.
Moderate changes have moderate potential for an adverse effect. They require a Changes Being Effected (CBE) supplement, implemented either after a 30-day waiting period or immediately, depending on the change.
Minor changes have minimal potential for an adverse effect. They are documented internally and reported in the next annual report, with no pre-review.

Classification is the most consequential decision in the process. Classify too low and you may distribute product without required FDA review; classify too high and you delay implementation unnecessarily. FDA’s Scale-Up and Postapproval Changes (SUPAC) guidances walk through common manufacturing changes for immediate-release solids, modified-release solids, and semisolid products, and recommend appropriate reporting categories.

Prior Approval Supplements

A PAS is the most restrictive pathway. You cannot distribute any product made with the change until FDA has reviewed and approved the supplement.¹ Commercial production under the new conditions waits, sometimes for months.

The regulation identifies categories of changes that typically require a PAS:

Adding, removing, or changing the amount of any active or inactive ingredient, or changing approved specifications.
Any change that requires new bioequivalence or bioavailability studies to confirm the product still performs the same way.
Switching sterilization methods, or adding or removing steps in an aseptic process.
Changes to how the active ingredient is manufactured when they could alter the impurity profile or the physical, chemical, or biological properties of the substance.
Most labeling changes, with narrow exceptions for safety-related updates and minor editorial corrections.
Container closure changes that could affect the impurity profile, such as switching from glass to plastic.

The list is illustrative, not exhaustive. Any change with substantial potential for an adverse effect falls here, even if it doesn’t match one of the enumerated examples. Facility changes, equipment upgrades, and process modifications can all require a PAS depending on the risk assessment.

Review Timelines

Under PDUFA performance goals for fiscal years 2023 through 2027, FDA targets reviewing 90 percent of manufacturing supplements within 6 months of receipt. Efficacy supplements, which add a new indication or expand approved use, follow a 10-month standard review, or 6 months with priority review designation.³ These are goals, not guarantees. Complex submissions, inspection needs, and information requests can push the actual timeline further.

Pre-Approval Inspections

FDA may conduct a pre-approval inspection (PAI) of the manufacturing facility before granting approval on a PAS. The decision is risk-based, and inspections are more likely when a facility has never been inspected, when new buildings or equipment are involved, when the facility has undergone major changes since the last inspection, or when the review itself flags data integrity or quality concerns.⁴ FDA may use Remote Regulatory Assessments in some cases instead of on-site inspections. A PAI adds time, and site transfers or new facility additions should build that possibility into their timeline.

Changes Being Effected Supplements

Moderate changes carry enough risk to require FDA notification but not full pre-approval. The CBE pathway lets you implement faster while FDA reviews in the background.¹

CBE-30

With a CBE-30, you may begin distributing the modified product 30 days after FDA receives the supplement, provided FDA does not object during that window. The regulation places several types of changes here:

Container closure system changes that do not affect drug product quality, unless the change is significant enough to require a PAS or minor enough for the annual report.
For biologics and recombinant protein products, scaling up or down during finishing steps with different equipment, or replacing equipment with a different design that does not change process methodology.
Relaxing an acceptance criterion or dropping a test to match an official compendium, when consistent with FDA requirements.

The 30-day period is not automatic. Reviewers can raise objections within the window, and if they do, distribution of the modified product must stop until the concern is resolved.

CBE-0

A CBE-0 allows implementation the moment FDA receives the supplement. The most common use is safety labeling changes. When FDA sends a Safety Labeling Change notification letter and the applicant’s proposed revisions match what FDA required, the applicant can submit those labeling updates as a CBE-0 and begin distributing the revised labeling immediately.⁵ These typically affect boxed warnings, contraindications, warnings and precautions, drug interactions, and adverse reactions.

The Risk of Distributing Before Full Review

CBE-0 and CBE-30 are not risk-free. FDA conducts its full review after the supplement is filed, and if the review determines the change does not adequately demonstrate continued safety and effectiveness, FDA can issue a cease distribution order. The applicant must then stop distributing any product made with the change until the supplement is approved.⁶ Product already in the distribution chain and product in the warehouse both become unsellable until the issue is resolved. Applicants who underestimate the data package needed for a CBE supplement sometimes end up worse off than if they had filed a PAS from the start.

Annual Report Changes

Minor changes require no supplement and no prior review. You document them internally and report them in the next annual report for the application, which must be submitted within 60 days of the approval anniversary date.⁷ The regulation’s examples give a sense of the threshold:

Changes to comply with an official compendium such as the U.S. Pharmacopeia, except for relaxing an acceptance criterion, which is a CBE.
Removing or reducing an ingredient that only affects color.
Replacing equipment with identical design and operating principles.
Changing container size or shape for a nonsterile solid dosage form when the closure system stays the same and the dosage unit count does not change.
Extending expiration dating based on full shelf-life data from a protocol already approved in the NDA.
Adding or revising an analytical procedure that provides equal or better assurance of quality.
Adding or slightly modifying a code imprint on a solid oral dosage form, other than modified-release products.
Editorial labeling corrections or changes in how the product is described or supplied, provided dosage strength and form stay the same.

Missing the 60-day window rarely triggers immediate enforcement, but it creates a compliance gap that inspectors will note. A pattern of late or incomplete annual reports signals broader quality system problems.

Comparability Protocols

Applicants who expect to make recurring changes can front-load the analysis through a comparability protocol. The protocol lays out the specific tests, studies, and acceptance criteria that will demonstrate a particular type of manufacturing change does not adversely affect the product. Submitted and approved as a PAS, the protocol lets the applicant later implement covered changes at a reduced reporting category, such as a CBE supplement or annual report, instead of filing another PAS.

The reduced category applies only when the applicant performs the activities specified in the approved protocol and meets every predefined success criterion. Miss a criterion and the reduction is no longer justified, and the change reverts to the standard pathway, which usually means a PAS.⁸ The upfront investment pays off most for companies anticipating similar changes across multiple products or sites.

Submission Format and User Fees

All NDA and ANDA supplements must be submitted in electronic Common Technical Document (eCTD) format through the FDA Electronic Submissions Gateway. This applies to every supplement, amendment, and report, including submissions to applications originally filed before the eCTD requirement took effect.⁹ Noncompliant submissions will not be filed or received.

The submission package should include a complete description of the change, an analysis of its potential effects on the drug product, and supporting data such as validation reports, stability data, and redline comparisons of affected master documents. Changes affecting bioequivalence should also include comparative dissolution testing.

Fees matter to the planning conversation. For fiscal year 2026, PDUFA application fees for NDA supplements requiring clinical data are $4,682,003. Supplements that do not require clinical data, which covers most manufacturing supplements, carry a fee of $2,341,002.¹⁰ For ANDA holders, GDUFA sets separate fees, and the FY 2026 ANDA application fee is $358,247.¹¹ Minor changes reported in the annual report carry no user fee.

Expedited Review for Drug Shortages

When a post-approval change could help resolve or prevent a drug shortage, FDA’s Office of Pharmaceutical Quality will consider requests for expedited review of the PAS. The request must state the basis, typically that the product is on, or at risk of appearing on, the drug shortage list, and that the proposed change addresses the supply constraint.¹² Expedited review does not follow a fixed timeline. Completion depends on supplement complexity and available FDA resources. If review requires a multidisciplinary team, the internal project manager notifies all relevant assessment and inspection divisions of the need to expedite. Applicants can request expedited review at submission or at any point afterward if circumstances change.

1
eCFR. 21 CFR 314.70 – Supplements and Other Changes to an Approved NDA
2
eCFR. 21 CFR 314.97 – Supplements and Other Changes to an Approved ANDA
3
U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027
4
U.S. Food and Drug Administration. Compliance Program 7346.832 – Preapproval Inspections
5
U.S. Food and Drug Administration. SOPP 8419 – Section 505(o)(4) Required Safety Labeling Changes
6
U.S. Food and Drug Administration. Drug Product Distribution After a Complete Response Action to a Changes Being Effected Supplement
7
eCFR. 21 CFR 314.81 – Other Postmarketing Reports
8
U.S. Food and Drug Administration. Comparability Protocols for Human Drugs and Biologics – Chemistry, Manufacturing, and Controls Information Guidance for Industry
9
U.S. Food and Drug Administration. Electronic Common Technical Document (eCTD)
10
Federal Register. Prescription Drug User Fee Rates for Fiscal Year 2026
11
U.S. Food and Drug Administration. Generic Drug User Fee Amendments
12
U.S. Food and Drug Administration. Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls Changes